Combining Pirfenidone With Mycophenolate Mofetil for Systemic Sclerosis–Related Interstitial Lung Disease (Scleroderma Lung Study <scp>III</scp> ): An Investigator‐Initiated, Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Phase 2 Trial

Dinesh Khanna(University of Michigan), Marcin A. Trojanowski(Boston University), Gary M. Hunninghake(Hubei University of Science and Technology), Mary Beth Scholand(University of Utah), Ganesh Raghu(University of Washington), Maureen D. Mayes(The University of Texas Health Science Center), Richard McLain(University of Michigan), R. Boente(Indiana University School of Medicine), Jane E. Dematte(Northwestern University), Eric C. Kleerup, Iván O. Rosas(Brigham and Women's Hospital), Aryeh Fischer(University of Colorado Denver), Cathie Spino(University of Michigan), Jonathan Goldin(UCLA Health), Elana J. Bernstein(Columbia University), Virginia Steen(Georgetown University), Airi Harui(University of California, Los Angeles), Vivien Hsu(Rutgers, The State University of New Jersey), Donald P. Tashkin(University of California, Los Angeles), Vivek Nagaraja(Mayo Clinic in Arizona), Grace Hyun J. Kim(APLA Health), Paul F. Dellaripa(Brigham and Women's Hospital), Robyn T. Domsic(University of Pittsburgh), Jessica Gordon(Hospital for Special Surgery), Richard M. Silver(Medical University of South Carolina), Robert W. Simms(Dartmouth–Hitchcock Medical Center), Grace Ibrahim(University of California, Los Angeles), Joyce Lee(Inserm), Suiyuan Huang(University of Michigan), Yi‐Hsuan Tu(University of Michigan), Michael D. Roth(Johns Hopkins University), S. Samuel Weigt(University of California, Los Angeles)
ACR Open Rheumatology
November 26, 2025
Cited by 3


Related Papers